Block Listing Update

RNS Number : 2178Q

Futura Medical PLC

25 November 2016

 

For immediate release

25 November 2016

Futura Medical plc

("Futura" or "the Company")

Block Listing Update

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology makes the following update on its block listing, pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies. All figures relate to options over ordinary shares of 0.2 pence each.

The table below provides further detail.

Name of company:	Futura Medical plc
Name of scheme:	Unapproved Share Option Scheme ("USOS") EMI Share Option Scheme ("EMI")
Period of return:	From:	20 May 2016
	To:	24 November 2016
Number and class of securities not issued under the scheme(s)	USOS:	1,440,600
	EMI:	1,344,141
	Total:	2,784,741
Number of securities issued under the scheme(s) during the period Number of securities lapsed under the scheme(s) during the period (EMI adjustment to May return)	USOS:	Nil
	EMI: USOS: EMI:	Nil (284,279)    20,000
Balance under the scheme(s) of securities not yet issued at the end of the period	USOS:	1,156,321
	EMI:	1,364,141
	Total:	2,470,462
Number and class of securities originally admitted and the date of admission	USOS:	814,424 on 25 May 2011 and 1,202,280 on 8 October 2013
	USOS Total:	2,016,704
	EMI:	1,520,576 on 25 May 2011 and 1,467,720 on 8 October 2013
	EMI Total:	2,988,296
	Total:	5,005,000
Name of contact:	Derek Martin, Chief Financial Officer
Telephone number of contact:	[phone]

For further information please contact:

Futura Medical plc
James Barder, Chief Executive	Tel: [phone]
Email to: [e-mail]	www.futuramedical.com
N+1 Singer (Nominated Adviser and Broker)
Aubrey Powell / Liz Yong Corporate Finance	Tel:[phone]
For media enquiries please contact:
Buchanan
Mark Court / Sophie Cowles / Stephanie Watson	Tel: [phone]

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com

 

END

 

 

BLRPGGCUGUPQGAA